Overview
FARMAKEIO Pharmacy Network provides patient-specific compounded medications through custom compounding and pharmaceutical outsourcing, including a FDA-registered 503B facility that makes bioidentical hormone pellets. It offers both sterile and non-sterile formulations for areas like hormone therapy, weight loss, cognitive function, and sexual health, plus retail pharmacy services. The company ships to 49 states, Puerto Rico, and the U.S. Virgin Islands with free standard shipping to improve access and reduce delays. By combining nationwide outsourcing, compounding, and retail operations under family leadership and a patented pellet formula, its goal is to deliver customized, reliable medicines and expand production capacity for healthcare providers and patients.
Work here?Claim your company
Simplify's Take
What believers are saying
- FDA closed FarmaKeio Superior's 2022 warning letter on March 20, 2026.
- April 16, 2026 EVEXIAS and FarmaKeio publicly touted peptide review progress.
- The company keeps investing in facilities, signaling management still expects durable compounding demand.
What critics are saying
- FDA marked FarmaKeio Outsourcing's September 5, 2025 inspection open with Form 483 findings.
- Iowa charged FarmaKeio in June 2025; California seeks license revocation and Dan DeNeui sanctions.
- Compounded GLP-1 demand faces 2026 tightening as semaglutide and tirzepatide shortages normalize.
What makes FARMAKEIO Pharmacy Network unique
- Southlake 503B facility ships compounded medicines nationwide across 49 states and territories.
- Patented hormone pellets anchor FarmaKeio Outsourcing’s bioidentical hormone delivery franchise.
- Conway expansion added $2.29 million capacity and 74 Arkansas jobs in 2023.
Help us improve and share your feedback! Did you find this helpful?